Get the Stockscreener App
1.93
2.03%
-0.04
Pre-market:
1.97
0.04
+2.07%
Creative Medical Technology Holdings Inc stock is traded at $1.93, with a volume of 72,798.
It is down -2.03% in the last 24 hours and down -26.89% over the past month.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
See More
Previous Close:
$1.97
Open:
$1.97
24h Volume:
72,798
Relative Volume:
0.62
Market Cap:
$5.00M
Revenue:
$102.80K
Net Income/Loss:
$-5.32M
P/E Ratio:
-0.5079
EPS:
-3.8
Net Cash Flow:
$-5.45M
1W Performance:
-2.03%
1M Performance:
-26.89%
6M Performance:
-43.24%
1Y Performance:
-59.88%
1-Day Range:
$1.90
$2.06
1-Week Range:
$1.90
$2.10
52-Week Range:
$1.69
$6.90
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
Name
Creative Medical Technology Holdings Inc
Sector
Industry
Phone
480-399-2822
Address
211 E. OSBORN RD., PHOENIX
Compare CELZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
1.93 | 5.00M | 102.80K | -5.32M | -5.45M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Creative Medical Technology Holdings Inc Stock (CELZ) Latest News
Creative Foam buys medical supplier AccuMed from Lear - Plastics News
Venus Shines Again, ENZ To Be Delisted, SLP, CERT On Watch - RTTNews
Head-To-Head Contrast: Atara Biotherapeutics (NASDAQ:ATRA) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
Exosomes Drug Market Projected To Witness Substantial Growth, - openPR.com
Mergers & Acquisitions Tracker - Plastics News
Longevity Health to combine with 20/20 BioLabs in all-stock deal (XAGE:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Exosomes Market Detailed In New Research Report 2025 | Bio-Techne, QIAGEN, Lonza, System Biosciences, LLC - newstrail.com
CELZ stock touches 52-week low at $1.9 amid market challenges - Investing.com Canada
CELZ stock touches 52-week low at $1.9 amid market challenges By Investing.com - Investing.com South Africa
Creative Medical Technology files to sell 1.8M shares of common stock by selling shareholders - MSN
Pre-market Movers: ICCT, CTOR, PCVX, AIM... - RTTNews
Creative Medical Technology (NASDAQ:CELZ) versus Immunocore (NASDAQ:IMCR) Head to Head Comparison - Defense World
CELZ stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
CELZ stock touches 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is Roth Capital’s Forecast for CELZ FY2027 Earnings? - Defense World
Creative Medical Technology (CELZ) Expected to Announce Quarterly Earnings on Friday - Defense World
Creative Medical Technology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves expanded trial for back pain cell therapy By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings Secures FDA Clearance For Expanded Dosing In Back Pain Trial - Nasdaq
FDA approves expanded trial for back pain cell therapy - Investing.com India
Creative Medical Receives FDA Approval to Expand Dosing in Back Pain Trial -March 20, 2025 at 08:27 am EDT - MarketScreener
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - The Manila Times
FDA Green Light: Breakthrough Cell Therapy Shows Promise in Chronic Back Pain Treatment - Stock Titan
Nanoparticle Drug Delivery Market Growth, Generated - openPR.com
Creative Medical Technology Holdings Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Game-Changing: Family-Owned Business Thrives for Over a Century - GeeksULTD
Just Revealed: Crescent Market Beaumont Family-Owned for 100+ Years - GeeksULTD
Apple Stock Forecast: Where Will It Be In 5 Years? - GeeksULTD
Revolutionary: Stem Cell Therapy Puts Creative Medical on Profit Track - GeeksULTD
Sexual Assault in South Sudan: Experts Stunned by Breakthrough Technology - GeeksULTD
Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) Shift From Loss To Profit - Yahoo
When Will Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Become Profitable? - Simply Wall St
Delaware Court Just Changed the Game for Big Business - GeeksULTD
Shocking: Trump Tariffs Spark Market Sell-Off - GeeksULTD
Trump Tariffs in Chaos: Markets React - GeeksULTD
Breaking: Trump Trade War Exposes Hidden Dangers - GeeksULTD
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. SEC 10-K Report - TradingView
Hyde Park Capital Advises Infiniti Medical on its Sale to CIMA Animal Health, a Portfolio Company of Incline Equity Partners - The Malaysian Reserve
Exosomes Drug Market Detailed In New Research Report 2025 | Thermo Fisher Scientific, Inc., Bio-Techne - openPR
Exosomes Market Projected To Witness Substantial Growth, 2025-2032: Bio-Techne, QIAGEN, Lonza, Miltenyi - EIN News
Creative Medical Technology secures $3.7 million through warrants By Investing.com - Investing.com Australia
Where are the Opportunities in (CELZ) - Stock Traders Daily
Creative Medical Technology secures $3.7 million through warrants - Investing.com India
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross - EIN News
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds - The Manila Times
Heritage Distilling Co. Announces Recent Achievements and Key Milestones for Salute Series Line of Premium Whiskeys - The Manila Times
Creative Medical Technology Holdings Announces Agreements For Exercise Of Warrants For $3.7 Million Gross Proceeds - MENAFN.COM
Can This $3.7M Cash Injection Fuel Creative Medical's Next Growth Phase? - StockTitan
Creative Medical Technology Holdings Inc Stock (CELZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Creative Medical Technology Holdings Inc Stock (CELZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finger Michael H. | Director |
Feb 18 '25 |
Sale |
5.00 |
750 |
3,750 |
1,101 |
2.04%
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):